Designing for Execution: Bridging Scientific Ambition & Operational Reality in Biomarker-Enabled Trials

• What role should biomarker operations play in protocol design, and how should site feasibility, sample collection requirements, patient burden, and operational realities inform those decisions?
• How can translational, biomarker operations, clinical operations, laboratory, and CRO partners come together earlier to anticipate operational challenges and plan the end-to-end journey from sample collection through testing, analysis, and data delivery?
• What does successful execution look like, and how can operational metrics, technology, and lessons learned improve visibility, scalability, and delivery of biomarker strategies across studies?

Moderated by:

Speakers:

Anu Ravi

Director, Clinical Operations

Revolution Medicines

Maria Gujral

Executive Director, Clinical Operations Capabilities & Standards

Legend Biotech

Benoit destenaves

Head Senior Director, Oncology Translational Medicine Operations & Experimental Oncology

AstraZeneca

Sherri Collins

Director, Project Management

TruTechnologies